Company News 22 Jan 2025 Orthocell Accelerates Global Expansion: Five New Country Regulatory Submissions Planned in 2025 On the back of outstanding early sales traction for Remplir™ in Australia, New Zealand and Singapore, Orthocell has announced that… Orthocell
Company News 20 Jan 2025 Orthocell receives $3.18m R&D tax incentive refund Orthocell has announced that it has received a $3.18 million R&D Tax Incentive Refund for the 2023/2024 financial year. Orthocell
Company News 08 Jan 2025 OCC Quarterly Report | Quarter ended 31 December 2024 Orthocell has recorded a third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter. Orthocell
Company News 19 Dec 2024 Orthocell Submits U.S. FDA Regulatory Application Orthocell has announced the submission of its U.S. FDA 510(k) regulatory application for clearance to commercially distribute Remplir™ into the… Orthocell
Company News 12 Dec 2024 Orthocell Achieves Major Milestone with First Sales of Remplir™ in Singapore Orthocell has today announced the achievement of first sales of Remplir™ in Singapore, marking another significant milestone in its global… Orthocell
Company News 02 Dec 2024 Orthocell successfully completes US FDA 510(k) regulatory study for Remplir™ Orthocell has today reached another significant milestone with the successful completion of its Remplir™ 510(k) nerve repair regulatory study, validating… Orthocell
Company News 27 Nov 2024 Orthocell Appoints Exclusive Distributor to Commence Sales of Remplir™ in Singapore Orthocell has announced that it has appointed Device Technologies Asia as the exclusive distributor of market leading peripheral nerve repair… Orthocell
Company News 11 Nov 2024 Appointment of Key US Executives to Lead Remplir™ Launch Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplir™ following the expected US… Orthocell
Company News 25 Oct 2024 $17 million placement to fund US launch of Remplir™ and drive further growth Orthocell has today announced that it has received firm commitments for a $17 million capital raising via an institutional placement. Orthocell
Company News 08 Oct 2024 Orthocell Receives Regulatory Approval for Remplir™ in Singapore Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of… Orthocell
